Human Helicase RECQL4 Drives Cisplatin Resistance in Gastric Cancer by Activating an AKT–YB1–MDR1 Signaling Pathway
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Elevation of the DNA-unwinding helicase RECQL4, which participates in various DNA repair pathways, has been suggested to contribute to the pathogenicity of various human cancers, including gastric cancer. In this study, we addressed the prognostic and chemotherapeutic significance of RECQL4 in human gastric cancer, which has yet to be determined. We observed significant increases in RECQL4 mRNA or protein in >70% of three independent sets of human gastric cancer specimens examined, relative to normal gastric tissues. Strikingly, high RECQL4 expression in primary tumors correlated well with poor survival and gastric cancer lines with high RECQL4 expression displayed increased resistance to cisplatin treatment. Mechanistic investigations revealed a novel role for RECQL4 in transcriptional regulation of the multidrug resistance gene MDR1, through a physical interaction with the transcription factor YB1. Notably, ectopic expression of RECQL4 in cisplatin-sensitive gastric cancer cells with low endogenous RECQL4 was sufficient to render them resistant to cisplatin, in a manner associated with YB1 elevation and MDR1 activation. Conversely, RECQL4 silencing in cisplatin-resistant gastric cancer cells with high endogenous RECQL4 suppressed YB1 phosphorylation, reduced MDR1 expression, and resensitized cells to cisplatin. In establishing RECQL4 as a critical mediator of cisplatin resistance in gastric cancer cells, our findings provide a therapeutic rationale to target RECQL4 or the downstream AKT–YB1–MDR1 axis to improve gastric cancer treatment. Cancer Res; 76(10); 3057–66. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537 · cited 1×
“The most prominent mode of its action is to initiate an intrinsic apoptotic pathway through DNA damage response activation (2).”
BackgroundCisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335 · cited 1×
“Also, constitutive activation of DNA damage response (DDR) pathways owing to elevated expression of DNA repair genes also contributes to chemo resistance by efficient reversal of cisplatin-DNA adducts (6).”
BackgroundMolecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760
Wang, L. L., Gannavarapu, A., Kozinetz, C. A., Levy, M. L., Lewis, R. A., Chintagumpala, M. M., Ruiz-Maldanado, R., Contreras-Ruiz, J., Cunniff, C., Erickson, R. P., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.9.669 · Cited by 338 · cited 1×
“Mutational loss of RECQL4 is associated with increased risk for osteosarcoma development in RTS patients (15).”
BackgroundRietveld, C. A., Esko, T., Davies, G., Pers, T. H., Turley, P., Benyamin, B., Chabris, C. F., Emilsson, V., Johnson, A. D., Lee, J. J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404623111 · Cited by 258
Cited by
5-methylcytosine promotes pathogenesis of bladder cancer through stabilizing mRNAs
Chen, X., Li, A., Sun, B.-F., Yang, Y., Han, Y.-N., Yuan, X., Chen, R.-X., Wei, W.-S., Liu, Y., Gao, C.-C., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0361-y · Cited by 801
Self-citationHuang, X., Li, Z., Zhang, Q., Wang, W., Li, B., Wang, L., Xu, Z., Zeng, A., Zhang, X., Zhang, X., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0969-3 · Cited by 476
Wnt/beta-catenin signaling confers ferroptosis resistance by targeting GPX4 in gastric cancer
Wang, Y., Zheng, L., Shang, W., Yang, Z., Li, T., Liu, F., Shao, W., Lv, L., Chai, L., Qu, L., et al. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-022-01008-w · Cited by 422
A novel long noncoding RNA HOXC-AS3 mediates tumorigenesis of gastric cancer by binding to YBX1
Zhang, E., He, X., Zhang, C., Su, J., Lu, X., Si, X., Chen, J., Yin, D., Han, L., & De, W. (2018) · Genome Biology · doi:10.1186/s13059-018-1523-0 · Cited by 282
The emerging role of MicroRNA-182 in tumorigenesis; a promising therapeutic target
Sameti, P., Tohidast, M., Amini, M., Bahojb Mahdavi, S. Z., Najafi, S., & Mokhtarzadeh, A. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02972-0 · Cited by 32
“Although Cisplatin (CDDP) is considered an essential component of chemotherapy for the treatment of GC, unfortunately, after several periods of use, the resistance of GC cells to this drug limits the chemotherapy process [47].”
Background
Metadata
- Authors
- Mo, D., Fang, H., Niu, K., Liu, J., Wu, M., Li, S., Zhu, T., Aleskandarany, M. A., Arora, A., Lobo, D. N., Madhusudan, S., Balajee, A. S., Chi, Z., & Zhao, Y.
- Venue
- Cancer Research
- Published
- 2016-05-12
- Volume
- 76
- Issue
- 10
- Pages
- 3057-3066
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2308504656
- Cited by
- 101
- References
- 5
- FWCI
- 3.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Human Helicase RECQL4 Drives Cisplatin Resistance in Gastric Cancer by Activating an AKT–YB1–MDR1 Signaling Pathway. https://app.cochat.ai/papers/10.1158/0008-5472.can-15-2361
- The paper
- Mo, D., Fang, H., Niu, K., Liu, J., Wu, M., Li, S., Zhu, T., Aleskandarany, M. A., Arora, A., Lobo, D. N., Madhusudan, S., Balajee, A. S., Chi, Z., & Zhao, Y. (2016). Human Helicase RECQL4 Drives Cisplatin Resistance in Gastric Cancer by Activating an AKT–YB1–MDR1 Signaling Pathway. Cancer Research. https://doi.org/10.1158/0008-5472.can-15-2361
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.